Vytorin sees growth without nibbling on Zetia

Share this article:

Since launching last year, Schering-Plough's dual-action cholesterol-lowering product Vytorin has risen to sixth among the top nine lipid-lowering drugs, without cannibalizing sales of the firm's blockbuster cholesterol pill, Zetia.
Vytorin's 5 million prescriptions had rung up $496 million in sales as of July, according to IMS Health. And Vytorin has hardly caused a Zetia collapse. As of August, Vytorin had nabbed 7.7 percent of new prescriptions, outpacing Pravachol (pravastatin) at 6.7 percent and Crestor (rosuvastatin) at 5.8 percent.
Zetia holds 7.5 percent of new scripts and, over the same period, has reaped $1.1 billion in sales, IMS Health data show.
Vytorin is a combination of Zetia (ezetimibe) and Merck's Zocor (simvastatin). Simvastatin reduces production of LDL, or "bad cholesterol," in the liver, while Zetia reduces absorption of it in the intestine. Schering-Plough sells Vytorin and Zetia through a partnership with Merck.

 

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...